Immutep Ltd Net Assets
Immutep Ltd net assets. Based on the latest financial reports, Immutep Ltd (IMM) has net assets worth AU$143.64 Million AUD (≈ $101.63 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$156.98 Million ≈ $111.08 Million USD) and total liabilities (AU$13.35 Million ≈ $9.44 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore IMM shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$143.64 Million |
| % of Total Assets | 91.5% |
| Annual Growth Rate | 18.95% |
| 5-Year Change | 96.03% |
| 10-Year Change | 306.7% |
| Growth Volatility | 169.37 |
Net Assets of Immutep Ltd (2000–2025)
Net assets of Immutep Ltd from 2000 to 2025. This chart illustrates how Immutep Ltd's net assets have evolved over time, based on quarterly financial data. See Immutep Ltd net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Immutep Ltd (2000–2025)
The table below shows the annual net assets of Immutep Ltd from 2000 to 2025. For live market cap and overall valuation, see IMM market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$143.64 Million ≈ $101.63 Million |
-24.21% |
| 2024-06-30 | AU$189.52 Million ≈ $134.10 Million |
+38.87% |
| 2023-06-30 | AU$136.47 Million ≈ $96.56 Million |
+45.06% |
| 2022-06-30 | AU$94.08 Million ≈ $66.57 Million |
+28.40% |
| 2021-06-30 | AU$73.27 Million ≈ $51.84 Million |
+120.04% |
| 2020-06-30 | AU$33.30 Million ≈ $23.56 Million |
+36.54% |
| 2019-06-30 | AU$24.39 Million ≈ $17.26 Million |
-27.25% |
| 2018-06-30 | AU$33.52 Million ≈ $23.72 Million |
+26.34% |
| 2017-06-30 | AU$26.53 Million ≈ $18.77 Million |
-24.87% |
| 2016-06-30 | AU$35.32 Million ≈ $24.99 Million |
+43.05% |
| 2015-06-30 | AU$24.69 Million ≈ $17.47 Million |
+9.28% |
| 2014-06-30 | AU$22.59 Million ≈ $15.99 Million |
-22.76% |
| 2013-06-30 | AU$29.25 Million ≈ $20.70 Million |
-21.29% |
| 2012-06-30 | AU$37.16 Million ≈ $26.29 Million |
-32.56% |
| 2011-06-30 | AU$55.10 Million ≈ $38.99 Million |
+228.21% |
| 2010-06-30 | AU$16.79 Million ≈ $11.88 Million |
+826.20% |
| 2009-06-30 | AU$1.81 Million ≈ $1.28 Million |
-31.17% |
| 2008-06-30 | AU$2.63 Million ≈ $1.86 Million |
-35.46% |
| 2007-06-30 | AU$4.08 Million ≈ $2.89 Million |
-35.41% |
| 2006-06-30 | AU$6.32 Million ≈ $4.47 Million |
-24.29% |
| 2005-06-30 | AU$8.34 Million ≈ $5.90 Million |
+62.76% |
| 2004-06-30 | AU$5.13 Million ≈ $3.63 Million |
+65.73% |
| 2003-06-30 | AU$3.09 Million ≈ $2.19 Million |
-43.35% |
| 2002-06-30 | AU$5.46 Million ≈ $3.86 Million |
+31.82% |
| 2001-06-30 | AU$4.14 Million ≈ $2.93 Million |
+120.79% |
| 2000-06-30 | AU$1.88 Million ≈ $1.33 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Immutep Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 44408132200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Immutep Ltd Net Assets Breakdown (June 2025)
Immutep Ltd net assets breakdown by equity component as of June 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$535.07 Million | 372.52% |
| Other Comprehensive Income | AU$52.65 Million | 36.65% |
| Other Components | AU$1.00 | 0.00% |
| Total Equity | AU$143.64 Million | 100.00% |
Immutep Ltd Competitors by Market Cap
The table below lists competitors of Immutep Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Maniker F & G Co. Ltd
KQ:195500
|
$21.87 Million |
|
Daebo Magnetic Co.Ltd
KQ:290670
|
$21.87 Million |
|
Formetal Co. Ltd
KQ:119500
|
$21.88 Million |
|
OPCOM Holdings Bhd
KLSE:0035
|
$21.88 Million |
|
Aciselsan Acipayam Seluloz Sanayi Ve Ticaret AS
IS:ACSEL
|
$21.85 Million |
|
Kidoz Inc
V:KIDZ
|
$21.85 Million |
|
SP Systems Co.Ltd
KQ:317830
|
$21.78 Million |
|
Protasco Bhd
KLSE:5070
|
$21.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immutep Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 189,521,742 to 143,635,363, a change of -45,886,379 (-24.2%).
- Net loss of 61,434,165 reduced equity.
- Other comprehensive income increased equity by 22,583,096.
- Other factors decreased equity by 7,035,310.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-61.43 Million | -42.77% |
| Other Comprehensive Income | AU$22.58 Million | +15.72% |
| Other Changes | AU$-7.04 Million | -4.9% |
| Total Change | AU$- | -24.21% |
Book Value vs Market Value Analysis
This analysis compares Immutep Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.21x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.04x to 0.21x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-06-30 | AU$0.57 | AU$0.02 | x |
| 2005-06-30 | AU$0.52 | AU$0.02 | x |
| 2006-06-30 | AU$0.27 | AU$0.02 | x |
| 2007-06-30 | AU$0.16 | AU$0.02 | x |
| 2008-06-30 | AU$0.01 | AU$0.02 | x |
| 2009-06-30 | AU$0.00 | AU$0.02 | x |
| 2010-06-30 | AU$0.04 | AU$0.02 | x |
| 2011-06-30 | AU$0.13 | AU$0.02 | x |
| 2012-06-30 | AU$0.09 | AU$0.02 | x |
| 2013-06-30 | AU$0.07 | AU$0.02 | x |
| 2014-06-30 | AU$0.05 | AU$0.02 | x |
| 2015-06-30 | AU$0.06 | AU$0.02 | x |
| 2016-06-30 | AU$0.15 | AU$0.02 | x |
| 2017-06-30 | AU$0.13 | AU$0.02 | x |
| 2018-06-30 | AU$0.13 | AU$0.02 | x |
| 2019-06-30 | AU$0.07 | AU$0.02 | x |
| 2020-06-30 | AU$0.08 | AU$0.02 | x |
| 2021-06-30 | AU$0.12 | AU$0.02 | x |
| 2022-06-30 | AU$0.11 | AU$0.02 | x |
| 2023-06-30 | AU$0.16 | AU$0.02 | x |
| 2024-06-30 | AU$0.16 | AU$0.02 | x |
| 2025-06-30 | AU$0.10 | AU$0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immutep Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -42.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1218.02%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.09x
- Recent ROE (-42.77%) is above the historical average (-67.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | -98.09% | -1411.65% | 0.06x | 1.14x | AU$-5.48 Million |
| 2005 | -75.43% | -1114.93% | 0.06x | 1.09x | AU$-7.13 Million |
| 2006 | -67.34% | -2797.82% | 0.02x | 1.17x | AU$-4.89 Million |
| 2007 | -76.94% | -13647726.09% | 0.00x | 1.07x | AU$-3.55 Million |
| 2008 | -71.67% | -3254.06% | 0.02x | 1.07x | AU$-2.15 Million |
| 2009 | -162.53% | -10159.85% | 0.01x | 1.37x | AU$-3.13 Million |
| 2010 | -72.43% | -2321.57% | 0.03x | 1.13x | AU$-13.84 Million |
| 2011 | -38.26% | -1977.59% | 0.02x | 1.05x | AU$-26.59 Million |
| 2012 | -53.67% | -1311.89% | 0.04x | 1.12x | AU$-23.66 Million |
| 2013 | -52.06% | -496.54% | 0.09x | 1.12x | AU$-18.15 Million |
| 2014 | -59.06% | -549.84% | 0.10x | 1.12x | AU$-15.60 Million |
| 2015 | -130.22% | -1715.89% | 0.06x | 1.25x | AU$-34.62 Million |
| 2016 | -175.59% | -35426.72% | 0.00x | 1.20x | AU$-65.55 Million |
| 2017 | -35.30% | -227.54% | 0.12x | 1.32x | AU$-12.02 Million |
| 2018 | -38.02% | -484.55% | 0.06x | 1.40x | AU$-16.10 Million |
| 2019 | -66.72% | -11640.01% | 0.00x | 1.66x | AU$-18.71 Million |
| 2020 | -40.45% | -179.90% | 0.16x | 1.40x | AU$-16.80 Million |
| 2021 | -40.81% | -774.12% | 0.05x | 1.12x | AU$-37.23 Million |
| 2022 | -34.24% | -18906.51% | 0.00x | 1.09x | AU$-41.62 Million |
| 2023 | -29.23% | -1138.04% | 0.02x | 1.08x | AU$-53.54 Million |
| 2024 | -22.54% | -1111.84% | 0.02x | 1.06x | AU$-61.67 Million |
| 2025 | -42.77% | -1218.02% | 0.03x | 1.09x | AU$-75.80 Million |
Industry Comparison
This section compares Immutep Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $11,206,087
- Average return on equity (ROE) among peers: -128.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immutep Ltd (IMM) | AU$143.64 Million | -98.09% | 0.09x | $21.87 Million |
| Adalta Ltd (1AD) | $7.49 Million | -79.00% | 0.24x | $5.41 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $4.14 Million | -76.87% | 0.39x | $12.88 Million |
| ACRUX Ltd (ACR) | $11.28 Million | 0.00% | 0.07x | $2.61 Million |
| Actinogen Medical Ltd (ACW) | $346.99K | -440.69% | 0.34x | $92.21 Million |
| Argenica Therapeutics Ltd (AGN) | $7.67 Million | -62.81% | 0.24x | $8.63 Million |
| Arovella Therapeutics Ltd (ALA) | $3.77 Million | -28.27% | 0.24x | $42.76 Million |
| Anatara Lifesciences Ltd (ANR) | $535.97K | -364.70% | 1.14x | $1.40 Million |
| Alterity Therapeutics Ltd (ATH) | $16.68 Million | -32.69% | 0.05x | $108.75 Million |
| Amplia Therapeutics Ltd (ATX) | $8.61 Million | -25.79% | 0.06x | $32.32 Million |
| Avecho Biotechnology Ltd (AVE) | $51.55 Million | -176.92% | 0.34x | $32.81 Million |
About Immutep Ltd
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more